Effects of Psychostimulants and Antipsychotics on Serum Lipids in an Animal Model for Schizophrenia
Authors:
- Banny Silva Barbosa CorreiaBanny Silva Barbosa Correia
- João Victor NaniJNJoão Victor Nani
- Raniery Waladares RicardoRRRaniery Waladares Ricardo
- Danijela StanisicDSDanijela Stanisic
- Tássia Brena Barroso Carneiro CostaTássia Brena Barroso Carneiro Costa
- Mirian A. F. HayashiMHMirian A. F. Hayashi
- Ljubica TasicLTLjubica Tasic
Open Access
- 26 February 2021
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 9 (3) , 235
Abstract
Schizophrenia (SCZ) treatment is essentially limited to the use of typical or atypical antipsychotic drugs, which suppress the main symptoms of this mental disorder. Metabolic syndrome is often reported in patients with SCZ under long-term drug treatment, but little is known about the alteration of lipid metabolism induced by antipsychotic use. In this study, we evaluated the blood serum lipids of a validated animal model for SCZ (Spontaneously Hypertensive Rat, SHR), and a normal control rat strain (Normotensive Wistar Rat, NWR), after long-term treatment (30 days) with typical haloperidol (HAL) or atypical clozapine (CLZ) antipsychotics. Moreover, psychostimulants, amphetamine (AMPH) or lisdexamfetamine (LSDX), were administered to NWR animals aiming to mimic the human first episode of psychosis, and the effects on serum lipids were also evaluated. Discrepancies in lipids between SHR and NWR animals, which included increased total lipids and decreased phospholipids in SHR compared with NWR, were similar to the differences previously reported for SCZ patients relative to healthy controls. Administration of psychostimulants in NWR decreased omega-3, which was also decreased in the first episode of psychosis of SCZ. Moreover, choline glycerophospholipids allowed us to distinguish the effects of CLZ in SHR. Thus, changes in the lipid metabolism in SHR seem to be reversed by the long-term treatment with the atypical antipsychotic CLZ, which was under the same condition described to reverse the SCZ-like endophenotypes of this validated animal model for SCZ. These data open new insights for understanding the potential influence of the treatment with typical or atypical antipsychotics on circulating lipids. This may represent an outcome effect from metabolic pathways that regulate lipids synthesis and breakdown, which may be reflecting a cell lipids dysfunction in SCZ.Keywords
Funding Information
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (001)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (477760/2010-4)
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2018/24069-3)
This publication has 60 references indexed in Scilit:
- Lipidomics Reveals Early Metabolic Changes in Subjects with Schizophrenia: Effects of Atypical AntipsychoticsPLOS ONE, 2013
- Schizophrenia shows a unique metabolomics signature in plasmaTranslational Psychiatry, 2012
- Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophreniaGenome Medicine, 2012
- Potential metabolite markers of schizophreniaMolecular Psychiatry, 2011
- Spontaneously Hypertensive Rats (SHR) present deficits in prepulse inhibition of startle specifically reverted by clozapineProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2011
- Metabolome in schizophrenia and other psychotic disorders: a general population-based studyGenome Medicine, 2011
- The clinical utility of testicular cancer risk lociGenome Medicine, 2011
- Potential adverse effects of amphetamine treatment on brain and behavior: a reviewMolecular Psychiatry, 2008
- Neuroleptic Drugs Revert the Contextual Fear Conditioning Deficit Presented by Spontaneously Hypertensive Rats: A Potential Animal Model of Emotional Context Processing in Schizophrenia?Schizophrenia Bulletin, 2008
- The newly synthesized pool of dopamine determines the severity of methamphetamine‐induced neurotoxicityJournal of Neurochemistry, 2007